whitepaper
Beyond the lab: screening
Register to access the very latest research, insights and innovations including CRISPR activation screening, AI-aided screening and using nanofibrillar cellulose hydrogels.
List view / Grid view
Screening
Medical screening is a strategy used to identify the possible presence of an as-yet-undiagnosed disease in individuals without signs or symptoms.
whitepaper
Handbook: Advanced flow cytometry handbook
Don’t miss out on the easier way to do flow cytometry. Learn how to bring speed, throughput, multiplexing and miniaturization, to your bench.
webinar
Biophysics in kinase drug discovery: FBS to PROTAC® ternary complex characterisation
20 October 2023 | By Eurofins Discovery
Watch this webinar to learn how biophysics can be used in different cascade strategies where the goal is to identify and characterise fragments, compounds or active degraders targeting PIM3 kinase.
webinar
Complete aggregate and particle characterisation of protein, gene and cell therapies
4 October 2023 | By Halo Labs
Join us to learn about the importance of subvisible particle characterisation for better product stability, ensuring patient safety from early-phase development through USP 788 lot release testing.
whitepaper
ebook: Maximizing preclinical confidence in target efficacy and safety
This ebook outlines Euretos’ approach to target discovery and indication expansion. Whilst also discussing data-driven target selection.
whitepaper
Guide: Screening biologic candidates with nanoDSF
Read this guide about nanoDSF for high-resolution measurements of thermal stability parameters, common CQAs for biologics developability assessment.
news
New test promises better detection of elusive cervical cancers
Researchers have developed a novel test capable of detecting a form of cervical cancer that frequently eludes detection through traditional Pap tests.
whitepaper
Infographic: Biologics stability in early development
Stability attributes of biologic candidates are evaluated during early development workflows. Learn how to measure them with biophysical techniques.
webinar
Turning Plans into Reality: Real Examples of Custom Automation Projects
24 August 2023 | By Bio-Rad Laboratories Inc.
Watch our industry experts to learn about the tangible benefits and best practice of custom flow cytometry automation projects. You’ll discover how to reduce your challenges implementing tailored automation, controlling the quality of the data produced and improving the reliability of your data acquisition.
webinar
SH2 domains as a target class in cancer and inflammation
25 July 2023 | By Eurofins Discovery
New SH2 domain binding assays developed by Eurofins Discovery have been launched to support drug discovery initiatives in the protein-protein interaction space and in targeted protein degradation. We present small molecule case study data for important targets within this target class including STAT Transcription factors and Kinases.
webinar
Bridging the gap: using organ-on-a-chip as an experimental tool to develop (cost) effective therapeutics
25 July 2023 | By CN Bio
The webinar will explore primary concerns in drug discovery development and why drugs fail.
news
Rare cause of hereditary cancer missed in younger patients
US investigators find that some cases of Lynch syndrome, the most common hereditary cancer condition, are missed in younger patients under current screening guidelines.
whitepaper
Case study: Mitochondrial toxicity in drug discovery and development
The Agilent Seahorse XF assay platform has opened new avenues for examining mitochondrial health in a timely and effective manner.
whitepaper
Application note: Novel screening tools for TMEM175 drug discovery
In this article, learn about how TMEM175 is an exciting new target in normal physiology and in disease. Also, read about how the use of biomarkers in Alzheimer’s drug development will address many of the challenges currently encountered.
webinar
Cardiac and vascular safety liabilities using totality of evidence approach
27 June 2023 | By Eurofins Discovery
US-FDA recommend integration of both preclinical (S7B) and clinical (E14) data to improve risk assessment, reduce reliance on TQT clinical studies, streamlined drug-development, simplified decision-making processes, effective risk-communication.